Skip to main content
S&P 5007,765.36-0.47%DOW51,231.64+0.10%NASDAQ27,193.34-1.25%BTC$81,788.00-1.91%ETH$2,478.56-3.77%GOLD$4,172.90+0.38%OIL$91.02-0.51%
Smart Investors Daily
SID Premium
EM

OTC · EMMA

Emmaus Life Sciences, Inc.

Healthcare · Biotechnology

$0.06

Up+$0.00 (+0.10%)

Updated Oct 9, 2026, 4:02 AM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
702.52K
P/E ratio
-0.1
Dividend yield
0.00%
52-week range
$0.01 – $0.09
Volume
10.8K
Avg. volume
69.57K

Price performance · EMMA

EMMA price history

1M range · 14 trading sessions · Daily adjusted prices

Prices through Oct 8, 2026

EMMA closed at $0.06 after 14 trading sessions, down 11.58% for the selected period.

Last close
$0.06
Period change
-11.58%
Period low
$0.04
Period high
$0.07
Daily close
View OHLC price history
EMMA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 8, 2026$0.0628$0.0628$0.0603$0.060310.8K
Oct 5, 2026$0.0602$0.0602$0.0602$0.06022.03K
Oct 2, 2026$0.0585$0.0585$0.0422$0.042220.25K
Oct 1, 2026$0.065$0.065$0.0585$0.0653.3K
Sep 28, 2026$0.0632$0.0655$0.0632$0.06558.44K
Sep 25, 2026$0.0678$0.0678$0.0618$0.067814.11K
Sep 23, 2026$0.0631$0.0678$0.0617$0.06176.2K
Sep 22, 2026$0.0679$0.0679$0.065$0.06559.68K
Sep 21, 2026$0.064$0.064$0.064$0.0649.92K
Sep 18, 2026$0.065$0.0679$0.065$0.0679110.89K
Sep 17, 2026$0.06$0.065$0.04$0.0553345.5K
Sep 16, 2026$0.0679$0.0679$0.0555$0.061731.02K
Sep 15, 2026$0.0627$0.0641$0.0615$0.061520.97K
Sep 14, 2026$0.0682$0.0682$0.0682$0.068210K

Latest EMMA news

The latest Smart Investors Daily articles mentioning EMMA.

Stock researchCompany · Overview

EMMA research

Overview

Company profile and research snapshot.

Company profile

EMMAUS LIFE SCIENCES INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 31, 2026

Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer

TORRANCE, Calif., August 31, 2026--Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into an exclusive option agreement with Cedars-Sinai to continue investigating the clinical utility of L-glutamine oral powder in combination with chemotherapy, as a potential treatment for Pancreatic Ductal Adenocarcinoma (PDAC).

Benzinga · Nov 14, 2025

Emmaus Life Sciences Reports Quarterly Financial Results

Emmaus Life Sciences reported a 38% decline in net revenues for Q3 2025, attributed to generic L-Glutamine competition and lower sales in the Middle East North Africa region. The company experienced a net loss of $2.1 million and reduced operating expenses by 43%.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By